You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Targeting Covid-19 with a Therapeutic Interfering Particle

    SBC: ALEPH THERAPEUTICS INC            Topic: NIAID

    SUMMARYThe Covid-19 pandemic caused by Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) is currently the most important public health crisis in the world. Given the unprecedented scope of this disease, it is critical to explore novel strategies to mitigate this crisis. Aleph Therapeutics and UCSF have jointly developed eTIP1, a Therapeutic Interfering Particle. eTIP1 was developed under a DARPA ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  2. Rapid point-of-care detection of Chlamydia trachomatis in urine

    SBC: ELECTRONUCLEICS INC            Topic: NIAID

    Project Summary The goal of this project is to demonstrate feasibility of a system for the point-of-care (POC) detection of Chlamydia trachomatis (CT) in human urine samples that integrates a patented detector of pathogens based on identification of species-specific, nucleic acid (NA) sequences. The detector relies on a novel electromechanical signal transduction mechanism that enables the low-cos ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II)

    SBC: Tengen Biomedical Co            Topic: NIAID

    Development of Zika viral pseudoinfectious virus as zika vaccine candidate(Phase 2) Abstract Zika virus epidemics and the association of ZIKV infection with Guillain–Barré syndrome, and congenital disabilities, including microcephaly, led the World Health Organization to declare ZIKV a “Public Health Emergency of International Concern” in 2016. Since then, various ZIKV vaccine platforms hav ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  4. Small molecule inhibitors of influenza virus nucleoprotein

    SBC: ALEXANDER BIODISCOVERIES, LLC            Topic: NIAID

    Influenza is a continuing worldwide public health threat, with seasonal activity that is not adequately controlled by the yearly vaccine program. The severity of this problem is likely to increase with emergence of new influenza virus strains in the human population, and this situation is made even more complex by the COVID-19 pandemic. Both COVID-19 and the 2009 H1N1 influenza pandemics are remin ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Antibacterial nanoparticles as insecticide synergists and insect growth regulators for improved control of cockroach infestations

    SBC: APEX BAIT TECHNOLOGIES, INC.            Topic: NIAID

    PROJECT SUMMARY The prevalence of asthma in the United States is approximately 8% (andgt;25 million people). In African Americans, the prevalence is andgt;11%. A majority of asthma sufferers are sensitized to allergens, including those shed in the feces, saliva, and exuviae of cockroaches. Thus, exposure to cockroach infestation is recognized as both a significant risk factor for the development o ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Personalized anesthetic brain monitoring:Developing novel systems, sensors, and algorithms for aging, dementia, and Alzheimers disease patients

    SBC: PASCALL Systems, Incorporated            Topic: R

    PROJECT SUMMARY In the United States, nearly 100,000 patients receive general anesthesia and sedation daily to safely undergo surgical and non-surgical procedures. A high proportion of these patients are older than 65 years of age. These older patients are at higher risk of post-operative delirium and cognitive dysfunction. Many of these older patients have dementia, including mild cognitive impai ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Computational prediction of gut microbiome-mediated drug metabolism

    SBC: NEXILICO, INC.            Topic: 100

    Project Summary / Abstract Notwithstanding pre-clinical experiments and clinical trials performed to identify efficacy, side effects, and adverse drug reactions (ADRs), only 25-60% of patients respond favorably to prescribed drugs, leading to a cost of $30-$130 billion in the US annually. ADRs are partially attributed to the gut microbiome, i.e. the complex and dynamic community of microorganisms ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. A multitargeted nanocarrier inhibitor of undruggable transcription factors for treating castration resistant prostate cancer

    SBC: PARABON NANOLABS, INC.            Topic: 102

    Project Summary This project addresses the critical need for treatments of castration resistant prostate cancer (CRPC) by proposing to engineer and develop a novel, nanostructured pharmaceutical (P-TRIS5) which will target tumor cells and deliver two potent, synergistic therapeutics (an siRNA and a small molecule) to inhibit the androgen receptor and RUNX, two commonly implicated transcription fac ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Leveraging an academic-industry partnership to develop a cancer-specific mobile meditation app

    SBC: Calm.com, Inc.            Topic: 102

    1 Project Summary/Abstract2 Approximately 15.5 million US cancer patients/survivors experience a host of residual symptoms (e.g.,3 fatigue, anxiety, depression, pain, sleep disturbance) and reduced quality of life that are often not resolved with4 even the best-available current standard of care therapies. Residual symptom burden impairs cancer survivor5 functioning and leads to increased rates of ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Development of selective calpain-1 inhibitors for chronic pain

    SBC: 1910 GENETICS INC.            Topic: 105

    PROJECT SUMMARY Never in the history of the United States has the unmet medical need to develop novel, non-opioid therapeutics for chronic pain been more urgent than it is today. More than 65 million US adults suffer from chronic pain, resulting in almost $635 billion in annual healthcare costs. Despite their limited efficacy, and potential for addiction, tolerance, and impaired motor performance, ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government